Post Doctoral Research Associate FLORIDA A&M UNIVERSITY TALLAHASSEE, Florida
Oral delivery of lipophilic cannabinoids like cannabidiol (CBD) is limited by poor solubility, permeability, and first-pass metabolism. This study presents a novel, bio-inspired delivery platform using camel milk-derived exosomes surface-functionalized with mucoadhesive poloxamer-407. Exosomes (~1×10¹¹ particles/mL) were isolated via differential ultracentrifugation and coated with 10% w/v poloxamer layers confirmed by DSC and FT-IR. Post-coating analysis confirmed retention of vesicle integrity, size, and CD9/CD63 expression. In vivo pharmacokinetic studies in Sprague Dawley rats revealed an increase in the Cmax values across three groups: poloxamer-coated CBD-loaded exosomes (719.58 ± 27.63 ng/mL), CBD- loaded exosomes (448.90 ± 78.53 ng/mL), and the control formulation (163.39 ± 24.97 ng/mL). In-silico GastroPlus™ modeling using ACAT and PBPK modules indicated enhanced absorption in the duodenum (27.5%) and jejunum (60.25%). The formulation outperformed uncoated exosomes by 1.6-fold. This GRAS-compliant, scalable exosome–polymer hybrid platform holds strong translational promise for improving the oral bioavailability of BCS Class II/IV and biologicals.
Learning Objectives:
Upon completion, participant will be able to create a GRAS camel milk exosome–poloxamer coated hybrid formulation.
Upon completion, participant will be able to evaluate CBD oral bioavailability via in-vivo pharmacokinetics data
Upon completion, participant will be able to evaluate in-silico GastroPlus® modeling.
